EBS
Emergent BioSolutions Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow +0.8% ·
net new positions +11.1%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 71.56K | $475,495 | n/a | n/a |
| Q2 2026 | 77 | 0 | 32.10M | $268.98M | +5 | −5 |
| Q1 2026 | 79 | +5 | 31.51M | $261.75M | +9 | −4 |
| Q4 2025 | 74 | 0 | 30.66M | $378.98M | n/a | n/a |
| Q3 2025 | 18 | +2 | 16.19M | $142.77M | +2 | n/a |
| Q2 2025 | 13 | 0 | 14.86M | $94.78M | n/a | n/a |
| Q1 2025 | 10 | -1 | 7.86M | $38.21M | n/a | −1 |
| Q4 2024 | 11 | +1 | 7.58M | $72.46M | +1 | n/a |
| Q3 2024 | 9 | 0 | 6.09M | $50.89M | +1 | −1 |
| Q2 2024 | 9 | n/a | 4.41M | $30.11M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 4.26M | -2.2% | $37.60M | 0.0% | ▼ Trim | 2 | SEC ↗ ×7 |
| 2 | The Vanguard Group ✦ (passive) | 3.54M | -1.2% | $31.23M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 3 | State Street Global Advisors ✦ (passive) | 2.45M | +40.5% | $21.57M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.28M | 0.0% | $11.28M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 912.39K | -10.4% | $8.05M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 6 | Goldman Sachs Group ✦ | 620.98K | n/a | $5.48M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 586.25K | New | $5.17M | 0.0% | New | 1 | SEC ↗ ×5 |
| 8 | Morgan Stanley ✦ | 528.88K | n/a | $4.66M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Renaissance Technologies ✦ | 518.25K | -24.9% | $4.57M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 339.65K | +20.7% | $3.00M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | D. E. Shaw & Co. ✦ | 321.17K | -21.9% | $2.83M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 261.33K | -26.1% | $2.30M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 188.17K | +11.7% | $1.66M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | Wellington Management ✦ | 184.10K | +6.3% | $1.62M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 15 | Millennium Management ✦ | 77.82K | -89.7% | $686,408 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | JPMorgan Chase ✦ | 44.86K | n/a | $395,630 | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 17 | T. Rowe Price ✦ | 40.44K | +4.2% | $357,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 33.71K | New | $297,296 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $5.17M | 0.0% |
| Arrowstreet Capital | $297,296 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 187 holders, 43.00M shares, $335.12M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 17.80K sh · $126,202
Officer · 3.00K sh · $19,590
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology